Thromb Haemost 2009; 101(02): 225-226
DOI: 10.1160/TH08-12-0819
Theme Issue Editorial
Schattauer GmbH

Thrombotic microangiopathies as a prime example for translational medicine

Peter F. Zipfel
1   Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology and Friedrich-Schiller-University, Jena, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 16. Dezember 2008

Accepted: 16. Januar 2008

Publikationsdatum:
23. November 2017 (online)

 

 
  • References

  • 1 Skerka C, Jozsi M, Zipfel P. et al. Autoantibodies in hemolytic uremic syndrome (HUS). Thromb Haemost 2009; 101: 227-232.
  • 2 Bresin E, Gastoldi S, Diana E. et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenia purpura and evidence of anti-adamts13 autoantibodies. Thromb Haemost 2009; 101: 233-238.
  • 3 Claus R, Bockmeyer C, Budde U. et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-247.
  • 4 Gerth J, Schleussner E, Kentouche K. et al. Pregnancy- associated thrombotic thrombocytopenic purpura. Thromb Haemost 2009; 101: 248-251.
  • 5 Müthing J, Schweppe C, Karch H. et al. Shiga toxins, glycosphingolipid diversity and endothelial cell injury. Thromb Haemost 2009; 101: 252-264.
  • 6 Amann K, Benz K. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uremic syndrome (HUS) / thrombocytic thrombopenic purpura (TTP). Thromb Haemost 2009; 101: 265-270.
  • 7 Licht C, Fremeaux-Bacchi V. Hereditary and Acquired Complement Dysregulation in Membranoproliferative Glomerulonephritis. Thromb Haemost 2009; 101: 271-278.